title: A randomized trial of cisplatin, vinblastine, and bleomycin versus cyclophosphamide, aclacinomycin, and cisplatin in epithelial ovarian cancer.
abstract: After primary cytoreductive surgery, a randomized clinical trial was conducted in women with epithelial ovarian cancer to compare the impact on survival between PVB chemotherapy, consisting of cisplatin, vinblastine and bleomycin, and CAP chemotherapy, consisting of cyclophosphamide, aclacinomycin and cisplatin. There were 148 evaluable patients. One hundred and five patients with stage II, III and IV were analyzed in this study, 49 of them received PVB chemotherapy while the remaining 56 patients received CAP chemotherapy. Sixty-four patients fulfilled the criteria for clinical remission set by the Tokai Ovarian Tumor Study Group [Gynecol Oncol 1993;48:342-348]. The remission rate was 73 and 50% in the PVB and CAP groups, respectively, and showed a significant advantage for the PVB group (p = 0.0139). Moreover, the recurrence rate was 44% in the PVB group and 61% in the CAP group after clinical remission, although there was no significant difference between the two groups. The final survival rate was 32% in the PVB group and 24% in the CAP group. There was a significant difference of survival rate between both groups at 24 months (p = 0.0378) and 48 months (p = 0.0450), but finally no significant difference was found at 96 months (p = 0.0660). Compared to the CAP regimen, the PVB combination has a significantly higher efficacy in remission, but there was no significant difference in the long-term survival rate. Furthermore, multivariate analysis demonstrated that the PVB chemotherapy improved the survival, but it was not significant. The authors conclude that PVB chemotherapy may be more effective than CAP chemotherapy for epithelial ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Tokuhashi
authors.forename: F
authors.initials: F
authors.lastname: Kikkawa
authors.forename: K
authors.initials: K
authors.lastname: Tamakoshi
authors.forename: N
authors.initials: N
authors.lastname: Suganuma
authors.forename: K
authors.initials: K
authors.lastname: Kuzuya
authors.forename: Y
authors.initials: Y
authors.lastname: Arii
authors.forename: M
authors.initials: M
authors.lastname: Kawai
authors.forename: S
authors.initials: S
authors.lastname: Hattori
authors.forename: I
authors.initials: I
authors.lastname: Kobayashi
authors.forename: Y
authors.initials: Y
authors.lastname: Furuhashi
authors.forename: N
authors.initials: N
authors.lastname: Nakashima
authors.forename: Y
authors.initials: Y
authors.lastname: Tomoda
mesh_terms: D015250:Aclarubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D014747:Vinblastine / Q000627:therapeutic use
chemical_list: C011157:aclacinomycins; D001761:Bleomycin; D014747:Vinblastine; D015250:Aclarubicin; D003520:Cyclophosphamide; D002945:Cisplatin